Histone deacetylase inhibitors sensitize tumour cells for cytotoxic effects of natural killer cells

Mareike Schmudde, André Braun, Daniela Pende, Jürgen Sonnemann, Ulrike Klier, James F. Beck, Lorenzo Moretta, Barbara M. Bröker

Research output: Contribution to journalArticle

47 Citations (Scopus)

Abstract

Histone deacetylase inhibitors (HDIs) are emerging as potent anti-tumour agents which induce cell cycle arrest, differentiation and/or apoptosis in many tumour cells. Furthermore, they render tumour cells more sensitive to other therapeutic regimens like ionizing radiation, chemotherapy and recombinant tumour necrosis factor-related apoptosis-inducing ligand (TRAIL). Here, we show that the HDIs suberoylanilide hydroxamic acid (SAHA; vorinostat), sodium butyrate (NaB) and MS-275 sensitized DAOY and PC3 tumour cells for the cytotoxic effects of IL-2-activated PBMCs. In 51Cr-release assays, blockade of the activating NK receptors DNAM-1, NKG2D and the NCRs completely abrogated tumour cell lysis, revealing that NK cells were the main effector cells involved. HDIs increased the tumour surface expression of ligands for the activating NK receptors NKG2D and DNAM-1 thereby facilitating tumour cell recognition by NK cells. These results suggest that the combination of HDIs and immunotherapy may be an effective strategy for anti-cancer therapy.

Original languageEnglish
Pages (from-to)110-121
Number of pages12
JournalCancer Letters
Volume272
Issue number1
DOIs
Publication statusPublished - Dec 8 2008

Fingerprint

Histone Deacetylase Inhibitors
Natural Killer Cells
Neoplasms
NK Cell Lectin-Like Receptor Subfamily K
Apoptosis
Ligands
Neurokinin-1 Receptors
Butyric Acid
Cell Cycle Checkpoints
Ionizing Radiation
Immunotherapy
Interleukin-2
Tumor Necrosis Factor-alpha
Drug Therapy
Therapeutics

Keywords

  • Histone deacetylase inhibitors
  • NK cells
  • SAHA
  • Sodium butyrate
  • Synergy

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Schmudde, M., Braun, A., Pende, D., Sonnemann, J., Klier, U., Beck, J. F., ... Bröker, B. M. (2008). Histone deacetylase inhibitors sensitize tumour cells for cytotoxic effects of natural killer cells. Cancer Letters, 272(1), 110-121. https://doi.org/10.1016/j.canlet.2008.06.027

Histone deacetylase inhibitors sensitize tumour cells for cytotoxic effects of natural killer cells. / Schmudde, Mareike; Braun, André; Pende, Daniela; Sonnemann, Jürgen; Klier, Ulrike; Beck, James F.; Moretta, Lorenzo; Bröker, Barbara M.

In: Cancer Letters, Vol. 272, No. 1, 08.12.2008, p. 110-121.

Research output: Contribution to journalArticle

Schmudde, Mareike ; Braun, André ; Pende, Daniela ; Sonnemann, Jürgen ; Klier, Ulrike ; Beck, James F. ; Moretta, Lorenzo ; Bröker, Barbara M. / Histone deacetylase inhibitors sensitize tumour cells for cytotoxic effects of natural killer cells. In: Cancer Letters. 2008 ; Vol. 272, No. 1. pp. 110-121.
@article{fbe65c43629d47c3aaa4d3f55568e6ee,
title = "Histone deacetylase inhibitors sensitize tumour cells for cytotoxic effects of natural killer cells",
abstract = "Histone deacetylase inhibitors (HDIs) are emerging as potent anti-tumour agents which induce cell cycle arrest, differentiation and/or apoptosis in many tumour cells. Furthermore, they render tumour cells more sensitive to other therapeutic regimens like ionizing radiation, chemotherapy and recombinant tumour necrosis factor-related apoptosis-inducing ligand (TRAIL). Here, we show that the HDIs suberoylanilide hydroxamic acid (SAHA; vorinostat), sodium butyrate (NaB) and MS-275 sensitized DAOY and PC3 tumour cells for the cytotoxic effects of IL-2-activated PBMCs. In 51Cr-release assays, blockade of the activating NK receptors DNAM-1, NKG2D and the NCRs completely abrogated tumour cell lysis, revealing that NK cells were the main effector cells involved. HDIs increased the tumour surface expression of ligands for the activating NK receptors NKG2D and DNAM-1 thereby facilitating tumour cell recognition by NK cells. These results suggest that the combination of HDIs and immunotherapy may be an effective strategy for anti-cancer therapy.",
keywords = "Histone deacetylase inhibitors, NK cells, SAHA, Sodium butyrate, Synergy",
author = "Mareike Schmudde and Andr{\'e} Braun and Daniela Pende and J{\"u}rgen Sonnemann and Ulrike Klier and Beck, {James F.} and Lorenzo Moretta and Br{\"o}ker, {Barbara M.}",
year = "2008",
month = "12",
day = "8",
doi = "10.1016/j.canlet.2008.06.027",
language = "English",
volume = "272",
pages = "110--121",
journal = "Cancer Letters",
issn = "0304-3835",
publisher = "Elsevier Ireland Ltd",
number = "1",

}

TY - JOUR

T1 - Histone deacetylase inhibitors sensitize tumour cells for cytotoxic effects of natural killer cells

AU - Schmudde, Mareike

AU - Braun, André

AU - Pende, Daniela

AU - Sonnemann, Jürgen

AU - Klier, Ulrike

AU - Beck, James F.

AU - Moretta, Lorenzo

AU - Bröker, Barbara M.

PY - 2008/12/8

Y1 - 2008/12/8

N2 - Histone deacetylase inhibitors (HDIs) are emerging as potent anti-tumour agents which induce cell cycle arrest, differentiation and/or apoptosis in many tumour cells. Furthermore, they render tumour cells more sensitive to other therapeutic regimens like ionizing radiation, chemotherapy and recombinant tumour necrosis factor-related apoptosis-inducing ligand (TRAIL). Here, we show that the HDIs suberoylanilide hydroxamic acid (SAHA; vorinostat), sodium butyrate (NaB) and MS-275 sensitized DAOY and PC3 tumour cells for the cytotoxic effects of IL-2-activated PBMCs. In 51Cr-release assays, blockade of the activating NK receptors DNAM-1, NKG2D and the NCRs completely abrogated tumour cell lysis, revealing that NK cells were the main effector cells involved. HDIs increased the tumour surface expression of ligands for the activating NK receptors NKG2D and DNAM-1 thereby facilitating tumour cell recognition by NK cells. These results suggest that the combination of HDIs and immunotherapy may be an effective strategy for anti-cancer therapy.

AB - Histone deacetylase inhibitors (HDIs) are emerging as potent anti-tumour agents which induce cell cycle arrest, differentiation and/or apoptosis in many tumour cells. Furthermore, they render tumour cells more sensitive to other therapeutic regimens like ionizing radiation, chemotherapy and recombinant tumour necrosis factor-related apoptosis-inducing ligand (TRAIL). Here, we show that the HDIs suberoylanilide hydroxamic acid (SAHA; vorinostat), sodium butyrate (NaB) and MS-275 sensitized DAOY and PC3 tumour cells for the cytotoxic effects of IL-2-activated PBMCs. In 51Cr-release assays, blockade of the activating NK receptors DNAM-1, NKG2D and the NCRs completely abrogated tumour cell lysis, revealing that NK cells were the main effector cells involved. HDIs increased the tumour surface expression of ligands for the activating NK receptors NKG2D and DNAM-1 thereby facilitating tumour cell recognition by NK cells. These results suggest that the combination of HDIs and immunotherapy may be an effective strategy for anti-cancer therapy.

KW - Histone deacetylase inhibitors

KW - NK cells

KW - SAHA

KW - Sodium butyrate

KW - Synergy

UR - http://www.scopus.com/inward/record.url?scp=53949108746&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=53949108746&partnerID=8YFLogxK

U2 - 10.1016/j.canlet.2008.06.027

DO - 10.1016/j.canlet.2008.06.027

M3 - Article

C2 - 18718708

AN - SCOPUS:53949108746

VL - 272

SP - 110

EP - 121

JO - Cancer Letters

JF - Cancer Letters

SN - 0304-3835

IS - 1

ER -